SANTA BARBARA, Calif.
, Feb. 10, 2020
/PRNewswire-PRWeb/ -- Palette Life Sciences, Inc., a medical device company dedicated to assisting healthcare professionals (HCPs) to improve patient outcomes in colorectal urologic and oncologic conditions and diseases, today announced the launch of the Solesta® Reimbursement Assistance Program.
Solesta is a minimally-invasive, and easily injectable viscous gel made from two polysaccharides, Non-Animal Stabilized Hyaluronic Acid (NASHA®) and Dextranomer (Dx) microspheres.1 Solesta is the only quick, nonsurgical treatment for fecal incontinence, administered in an outpatient setting without the need for anesthesia.2 HCPs can simply follow three steps at MySolesta.com to become trained in Solesta administration and technique. Studies have shown that Solesta can help patients return to a more active lifestyle (socializing, going to work, etc.) and reduces the depression and embarrassment that is often associated with bowel control problems.3
The new Solesta Reimbursement Assistance Program provides an easy and seamless reimbursement experience for physicians prescribing Solesta for their patients. The program minimizes barriers that can delay or prevent access to Solesta by providing personalized reimbursement support to physicians and their patients. Physicians simply complete the Service Request Form located on MySolesta.com and submit it to the Solesta Reimbursement Assistance Program. This one-step program for physicians and their staff assumes no financial risk for product acquisition. Once approved, Solesta will be shipped directly to the physician's office.
"In past years, it was nearly impossible for physicians and patients to receive reimbursement for Solesta. We physicians had to endure financial risk in ordering Solesta for our patients and patients often found the product unaffordable, at times," said Dr. Zuri Murrell
, Los Angeles
based colorectal surgeon and specialist. "The new Solesta Reimbursement Assistance Program mitigates the reimbursement problem. My office staff was pleasantly surprised with the simplicity and effectiveness of the new reimbursement program. In the short amount of time that the program has existed, many patients have received the Solesta treatment at a reasonable cost."
"Seeking reimbursement for any product can be a time-consuming process for you and your office staff. When it comes to product reimbursement for Solesta, we're here to help," said Richard Low
, Head of Marketing, Palette Life Sciences. "The program is designed to help offices save time and energy while keeping physicians and their staff informed every step of the way."
Other resources available at MySolesta.com include more detailed clinical and procedure training information for physicians, as well as education materials for patients in both written and video formats, so that they know what to expect with the Solesta treatment. The site also includes a Physician Locator for patients.
For more information on the Solesta Reimbursement Assistance Program, call 1-877-546-7150; email firstname.lastname@example.org or visit MySolesta.com.
Solesta®, a Non-Animal Stabilized Hyaluronic Acid (NASHA®) and dextranomer gel, is a tissue bulking agent that is injected into the submucosal layer of the anal canal for treatment of Fecal Incontinence in adults. It's a minimally invasive, outpatient procedure that improves Quality of Life and has been proven effective for up to 36 months.1 Learn more at MySolesta.com.
About Palette Life Sciences
Palette Life Sciences is focused on providing a wide range of products and services that improve quality of life for patients. Led by experienced healthcare executives, the initial company strategy is to transform applications of existing technologies to bring forward novel solutions for underserved conditions. Palette Life Sciences, Inc. is a wholly owned subsidiary of Pharmanest AB headquartered in Stockholm, Sweden
. Learn more at MySolesta.com and palettelifesciences.com.
1. Cerwinka WH, Scherz HC, Kirsch AJ. Endoscopic treatment of vesicoureteral reflux with dextranomer/hyaluronic acid in children. Adv Urol. 2008;513854.
2. Solesta [Package Insert]. Santa Barbara, CA
: Palette Life Sciences.
3. Graf W, Mellgren KE, et al; for NASHA Dx study group. Efficacy of dextranomer in stabilised hyaluronic acid for treatment of faecal incontinence: a randomised, shame-controlled trial. Lancet. 2011;377(9770):977-1003.
Solesta® and NASHA® are registered trademarks. All rights reserved.
Important Safety Information: http://www.mysolesta.com/important-safety-information
SOURCE Palette Life Sciences